Suppr超能文献

一种潜在的预后生物标志物SPC24促进肺癌的肿瘤发生和转移。

A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer.

作者信息

Zhou Juan, Yu Yang, Pei Yunfeng, Cao Chunping, Ding Chen, Wang Duping, Sun Li, Niu Guoping

机构信息

Department of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.

Department of Medical Oncology, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People's Republic of China.

出版信息

Oncotarget. 2017 Jul 4;8(39):65469-65480. doi: 10.18632/oncotarget.18971. eCollection 2017 Sep 12.

Abstract

RESULTS

SPC24 is over-expressed in clinical lung adenocarcinoma samples, and high level of is associated with advanced stages of lung tumors. Knocking down SPC24 repressed cell growth and promoted apoptosis. SPC24 deficiency reduced cancer cell migration as well. E-cadherin, one of the epithelial-mesenchymal transition markers, was up-regulated in the knockdown cells, along with down-regulation of N-cadherin and Vimentin. Oncomine expression analyses further confirmed that high level of SPC24 is associated with tumors from smokers, recurrent patients, or patients with shorter survivals.

PURPOSE AND METHODS

To reveal the role of SPC24, an important component of kinetochore, in the tumorigenesis of lung cancer, we performed Oncomine and immunohistochemistry (IHC) analyses for SPC24 in human lung adenocarcinoma tumors. We knocked down in two non-small cell lung cancer (NSCLC) cell lines, PC9 and A549, by siRNA and evaluated cell proliferation, apoptosis, and migration in the SPC24-deficient cells. Using a mouse xenograft model, we compared tumor growth of the knockdown and control cells. We further performed multiple Oncomine expression analyses for SPC24 in various lung cancer datasets with important clinical characteristics and risk factors, including survival, recurrence, and smoking status.

CONCLUSIONS

is a novel oncogene of lung cancer, and can serve as a promising prognostic biomarker to differentiate lung tumors that have various clinicopathological characteristics. The findings of the current study will benefit the diagnosis, management, and targeted therapy of lung cancer.

摘要

结果

SPC24在临床肺腺癌样本中过表达,其高水平与肺肿瘤的晚期阶段相关。敲低SPC24可抑制细胞生长并促进细胞凋亡。SPC24缺失也降低了癌细胞的迁移能力。上皮-间质转化标志物之一的E-钙黏蛋白在敲低细胞中上调,同时N-钙黏蛋白和波形蛋白下调。Oncomine表达分析进一步证实,SPC24的高水平与吸烟者、复发患者或生存期较短患者的肿瘤相关。

目的和方法

为揭示动粒的重要组成部分SPC24在肺癌发生中的作用,我们对人肺腺癌肿瘤中的SPC24进行了Oncomine和免疫组织化学(IHC)分析。我们通过小干扰RNA(siRNA)敲低两种非小细胞肺癌(NSCLC)细胞系PC9和A549中的SPC24,并评估SPC24缺陷细胞中的细胞增殖、凋亡和迁移情况。使用小鼠异种移植模型,我们比较了敲低细胞和对照细胞的肿瘤生长情况。我们还对具有重要临床特征和危险因素(包括生存、复发和吸烟状态)的各种肺癌数据集中的SPC24进行了多次Oncomine表达分析。

结论

SPC24是肺癌的一种新型癌基因,可作为一种有前景的预后生物标志物,用于区分具有不同临床病理特征的肺肿瘤。本研究结果将有助于肺癌的诊断、管理和靶向治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fe12/5630346/8a698b445cf5/oncotarget-08-65469-g001-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验